EGFR associated expression profiles vary with breast tumor subtype

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR/HER1) signaling is crucial for epithelial tumor growth.
• EGFR's role in breast cancer is complex and linked to estrogen receptor (ER) status.
• Investigating EGFR signaling in breast cancer subtypes using a genomics approach.

Purpose of the Study:

• To examine the sensitivity of breast cancer cell lines to EGFR inhibitors.
• To identify and characterize EGFR-associated gene expression signatures.
• To assess the prognostic value of these signatures in primary breast tumors.

Main Methods:

• In vitro testing of breast basal-like and luminal cell lines with EGFR inhibitors.
• Development of an EGFR-associated gene expression signature.
• In vivo evaluation of the signature in 241 primary breast tumors.

Main Results:

• Basal-like breast cancer cell lines demonstrated higher sensitivity to EGFR inhibitors and carboplatin compared to luminal lines.
• A synergistic effect was observed between carboplatin and cetuximab in basal-like lines.
• Three distinct EGFR-associated gene clusters were identified in vivo; two predicted poor patient outcomes.
• These poor prognostic signatures were prevalent in basal-like, HER2+/ER-, and Luminal B tumors.

Conclusions:

• Breast basal-like cell lines are sensitive to EGFR inhibitors and carboplatin, suggesting potential synergistic therapeutic combinations.
• EGFR-associated gene signatures hold prognostic value in breast cancer.
• These signatures correlate with tumor subtype and are linked to specific EGFR-RAS-MEK pathway gene expression.